Latest news for  (OTC:RGPKS) Stock

WIIM

CENX

STLD

Shares of steel and aluminum stocks are trading higher after reports President Trump plans additional 25% tariffs on steel and aluminum.

Barclays analyst Adam Seiden maintains Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) with a Equal-Weight and lowers the price target from $60 to $52.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Terex, Lowers Price Target to $52

Billionaire Bill Gates said in an interview last week that he is not a &#8220;Mars person&#8221; like Jeff Bezos or Elon Musk, saying he would rather continue to put his wealth into funding better nutrition and getting rid of diseases like malaria.
What Happened: &#8220;I am not a big Mars person,&#8221; Gates said in an interview with Ashley Christine published on YouTube on Friday while adding that he does not believe Earth&#8217;s neighboring planet is a &#8220;very hospitable place.&#8221;
Gates commended Musk and Bezos for their attempts at making space launches less expensive by reusing parts of the launch vehicle. 
&#8220;That&#8217;s a pretty great contribution because there are things that you want to do in space like putting up communication satellites like the Starlink service&#8230;,&#8221; he said. While Musk is the founder of space tech company SpaceX, Bezos is the founder of Blue Origin.
However, Gates is unsure about enabling human existence in space or on Mars. &#8220;&#8230;we&#8217;re not sure can we can put solar panels in space can (or) we put data centers in space (or) can we do chemical Manufacturing in space&#8230;,&#8221; he said.
Why It Matters: This is not the first time that Gates has expressed a lack of interest in space exploration.
&#8220;I don't think rockets are the solution. But maybe I&#8217;m missing something there,&#8221; <a href="https://www.benzinga.com/news/23/08/33660308/bill-gates-says-unlike-elon-musk-im-not-a-mars-person-and-would-rather-spend-money-on-vaccines-than">he said during an appearance</a> on Kara Swisher&#8217;s &#8220;Sway&#8221; podcast in 2023. 
Gates, Bezos, and Musk are among the<a href="https://www.benzinga.com/news/global/24/12/42406893/bill-gates-could-go-bankrupt-if-tesla-stock-surges-200-to-become-the-top-company-says-elon-musk"> top ten rich people</a> around the globe. While Musk tops the chart with a total net worth of $402 billion, Bezos is in the third position with a total net worth of $249 billion and Gates in the seventh position with a total net worth of $165 billion, according to the Bloomberg Billionaires Index.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43585701/tesla-ceo-elon-musk-vp-of-finance-address-allegations-of-tax-fraud-losses-were-high-for-many-years-so-carry-forward">Tesla CEO Elon Musk, VP Of Finance Address Allegations Of Tax Fraud: &#8216;Losses Were High For Many Years, So Carry Forward&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Bill Gates Would Rather Save Earth Than Colonize Mars — Unlike Elon Musk, Jeff Bezos: 'I'm Not a Big Mars Person… It's Not a Very Hospitable Place'

TMUS

T-Mobile shares are trading higher after the company's Starlink beta rollout expanded nationwide.

Offerings

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Receives Binding Commitments For Capital Raising Of A$40M Via Two Tranche Placement Of Fully Paid Ordinary Shares

Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Underweight and raises the price target from $20 to $22.

PAHC

Barclays Maintains Underweight on Phibro Animal Health, Raises Price Target to $22

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Overweight and raises the price target from $310 to $329.

AMGN

Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $329

Barclays analyst Brandon Oglenski maintains Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) with a Equal-Weight and lowers the price target from $52 to $50.

HUBG

Barclays Maintains Equal-Weight on Hub Group, Lowers Price Target to $50

AXSM

Axsome Therapeutics shares are trading higher after the company reached a settlement agreement with Teva Pharmaceuticals resolving all patent litigation related to its Auvelity product.

HYFM

Hydrofarm Holdings shares are trading lower after the company announced its board approved a 1-for-10 reverse stock split.

U.S. stock futures were higher this morning, with the Dow Jones futures gaining <a href="https://www.benzinga.com/quote/TSLA">around 150 points on Monday</a>.
Shares of Tesla, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell in today's <a href="https://www.benzinga.com/quote/TSLA">pre-market trading</a>.
Tesla CEO Elon Musk and Vice President of Finance Sendil Palani addressed allegations of the EV company evading taxes in posts on X over the weekend. The company did not evade tax but carried it forward as per an Internal Revenue Service (IRS) provision, they said.
Tesla shares fell 1.2% to $357.16 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) dipped 54.5% to $3.54 in pre-market trading after the company issued an update on BEACON-IPF, a Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) shares tumbled 25.2% to $40.75 in pre-market trading. Semtech shares fell around 10% on Friday after Baird cut its price target on the stock from $80 to $60.</li>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) declined 20.2% to $0.91 in pre-market trading after falling more than 5% on Friday.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) fell 19.6% to $11.21 in pre-market trading. Replimune announced inducement grants under Nasdaq Listing Rule 5635(c)(4).     </li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 9.5% to $12.11 in pre-market trading. Maze Therapeutics shares gained around 3% on Friday after the company announced that the first patient has been dosed in the company&#8217;s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease.</li>
<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) fell 6.6% to $33.00 in pre-market trading.</li>
<li>The Manitowoc Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTW#NYSE">MTW</a>) shares dipped 6.4% to $9.12 in pre-market trading.</li>
<li>Option Care Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) fell 6% to $29.13 in pre-market trading.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) fell 3.2% to $125.52 in pre-market trading.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) shares declined 2.1% to $50.20 in pre-market trading ahead of quarterly earnings.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

DOGZ

MAZE

OPCH

ORIS

PLRX

REPL

SMTC

TSLA

Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Barclays analyst Brandon Oglenski maintains Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) with a Overweight and raises the price target from $10 to $14.

ULCC

Barclays Maintains Overweight on Frontier Group Holdings, Raises Price Target to $14

FULL-YEAR 2025 FINANCIAL OUTLOOK
We are raising our full-year 2025 guidance to reflect the strength of our year-to-date financial performance and the accounting impact of Fleet Complete's conversion from Canadian accounting standards to U.S. GAAP.
<ul>
<li>Annual revenue is now expected to exceed $362.5 million, a $10 million increase from our prior guidance of approximately $352.5 million.</li>
<li>Adjusted EBITDA is now expected to exceed $75 million, a $2.5 million increase from our prior guidance of $72.5 million, with both figures inclusive of $5 million in secured annualized run-rate synergies.</li>
</ul>

Earnings

Guidance

AIOT

Powerfleet Raised Its 2025 Outlook: Now Expects Revenue To Exceed $362.5M, Up $10M From Prior $352.5M Guidance And Adjusted EBITDA To Exceed $75M, Up $2.5M From Prior

PLYA

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

ECARX announces Integration Of DeepSeek-R1 Model Into ECARX AutoGPT

Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/vrtx/earnings">closing bell, on Monday, Feb. 10, 2025.</a>
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly revenue of $2.78 billion, compared to $2.52 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 30, Vertex Pharmaceuticals announced it secured FDA approval for JOURNAVX. Also, the company announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access CASGEVY.
Vertex Pharmaceuticals shares fell 2.5% to close at $469.32 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Rating</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating and raised the price target from $535 to $550 on Jan. 31, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Mohit Bansal downgraded the stock from Overweight to Equal-Weight with a price target of $460 on Jan. 30, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Truist Securities analyst Joon Lee maintained a Buy rating and lowered the price target from $550 to $460 on Dec. 23, 2024. This analyst has an accuracy rate of 76%.</li>
<li>JP Morgan analyst Jessica Fye maintained an Overweight rating and cut the price target from $503 to $500 on Dec. 23, 2024. This analyst has an accuracy rate of 63%.</li>
<li>BMO Capital analyst Even Seigerman maintained an Outperform rating and cut the price target from $566 to $520 on Dec. 20, 2024. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying VRTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="626" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-1024x626.png" alt="" class="wp-image-774084" style="width:543px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-1024x626.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

VRTX

Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings

Barclays analyst Adrienne Yih maintains Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) with a Equal-Weight and lowers the price target from $11 to $10.

GOOS

Barclays Maintains Equal-Weight on Canada Goose Hldgs, Lowers Price Target to $10

PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. The company reported quarterly sales of $106.429 million which beat the analyst consensus estimate of $99.426 million by 7.04 percent. This is a 44.54 percent increase over sales of $73.635 million the same period last year.

Earnings Beats

PowerFleet Q3 2024 Adj. EPS $0.01, Inline, Sales $106.429M Beat $99.426M Estimate

-Data from KONFIDENT-S show patients on LTP average 1.7 HAE attacks per month and symptom relief for treated attacks in median 1.3 hours -
–Results confirm sebetralstat effective for on-demand treatment of attacks regardless of type of LTP therapy used, including an all-oral regimen.

KALV

KalVista Presents New Sebetralstat Data; Claims Data Show 40% Of Patients On Long-term Prophylaxis Have Gaps In Prescription Refills, Leading To Greater On-demand Use And Higher Rate Of LTP Discontinuation

Piper Sandler analyst Adam Maeder maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and lowers the price target from $260 to $233.

INSP

Piper Sandler Maintains Overweight on Inspire Medical Systems, Lowers Price Target to $233

Membership Int Ser 1985 Garbage Pail Kids Box Shares Of Beneficial Int

Comments

News

Latest news for (OTC:RGPKS) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga